Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction

Study Identifier:
ACH471-009
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete

Study Details

Medical Condition
  • Other
  • Unmapped
Study Drug
  • Drug: Danicopan
Date
Jan 2018 - May 2018
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 75 Years
Requirements Information
Sex
Female & Male
Age
18 - 75 Years

Study Details

Medical Condition
  • Other
  • Unmapped
Study Drug
  • Drug: Danicopan
Date
Jan 2018 - May 2018
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 75 Years years
Requirements Information

Protocol Summary

This was an open-label, nonrandomized, multi-center, single-dose, parallel group study to evaluate the effect of severe renal impairment (RI) on the safety, tolerability, pharmacokinetics, and pharmacodynamics of danicopan (ACH-0144471) compared to demographically-matched healthy participants with normal renal function.

Trial Locations

Location
Status
Location
Clinical Trial Site
Miami, Florida, United States, 33014
Status
N/A
Location
Clinical Trial Site
Orlando, Florida, United States, 32809
Status
N/A
Location
Clinical Trial Site
Minneapolis, Minnesota, United States, 55404
Status
N/A
Location
Clinical Trial Site
Saint Paul, Minnesota, United States, 55114
Status
N/A